Literature DB >> 11562767

Expression of hepatocyte growth factor/scatter factor, its activator, inhibitors and the c-Met receptor in human cancer cells.

C Parr1, W G Jiang.   

Abstract

Hepatocyte growth factor/scatter factor (HGF/SF), a cytokine associated with cancer cell migration and invasion, is synthesised as pro-HGF/SF and requires activation by factors such as the HGF activator (HGFA). The present study examined the expression of HGF/SF, HGFA, the two inhibitors to HGFA action known as hepatocyte growth factor activator inhibitors type 1 and 2 (HAI-1 and HAI-2), and the HGF/SF receptor, c-Met. We examined a variety of normal and cancer cells, which included breast, prostate, colon, bladder, liver, lung, and pancreatic cancer cell lines. The cell lines all displayed different patterns of expression, and in some of the cancer cell lines the concomitant expression of the HGF/SF, c-Met, HGFA and HAI genes was observed. The only cell line to produce a significant amount of HGF/SF was the human fibroblasts (MRC-5) which also co-expressed the c-Met and HGFA genes to allow autocrine regulation of HGF/SF stimulation, and importantly displayed little or no inhibitor presence to suppress the biological function of HGF/SF. The highly invasive breast cancer cells (MDA MB-231) expressed large amounts of both c-Met and HGFA, to enable maximum influence from HGF/SF and did not express the HAI-1 gene at all, which suggests a shift in the activation-inhibition balance to enhance metastatic potential. In contrast, the breast cancer cells of low invasive nature (MCF-7) displayed a low level of c-Met and HGFA expression, while expressing the HAI genes to a high degree. However, there was no correlation between HAI-1 and HAI-2 expression. Interestingly, there appeared to be an inverse correlation between the degree of HGFA and HAI-1 expression, which may influence the metastatic ability of the cancer cells. This study has shown that c-Met, HGF/SF and its activator and inhibitors are expressed in different patterns in cancer cells and in normal cells. The balance between HGF/SF activation and HGFA inhibition is critical to the metastatic potential of the tumour cells, and the invasive nature of the cancer cell lines correlated to the degree of c-Met and/or HGFA presence along with HAI-1 expression.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11562767

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  34 in total

1.  HGF/SF increases tumor blood volume: a novel tool for the in vivo functional molecular imaging of Met.

Authors:  Galia Tsarfaty; Gideon Y Stein; Sharon Moshitch-Moshkovitz; Dafna W Kaufman; Brain Cao; James H Resau; George F Vande Woude; Ilan Tsarfaty
Journal:  Neoplasia       Date:  2006-05       Impact factor: 5.715

2.  Alternative proteolytic processing of hepatocyte growth factor during wound repair.

Authors:  Nils Buchstein; Daniel Hoffmann; Hans Smola; Sabina Lang; Mats Paulsson; Catherin Niemann; Thomas Krieg; Sabine A Eming
Journal:  Am J Pathol       Date:  2009-04-23       Impact factor: 4.307

3.  Priming cancer cells for drug resistance: role of the fibroblast niche.

Authors:  Wei Bin Fang; Min Yao; Nikki Cheng
Journal:  Front Biol (Beijing)       Date:  2014-02-01

4.  Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer.

Authors:  Zhenfu Han; Peter K W Harris; Darin E Jones; Ryan Chugani; Tommy Kim; Manjula Agarwal; Wei Shen; Scott A Wildman; James W Janetka
Journal:  ACS Med Chem Lett       Date:  2014-10-09       Impact factor: 4.345

5.  Expression of serine protease SNC19/matriptase and its inhibitor hepatocyte growth factor activator inhibitor type 1 in normal and malignant tissues of gastrointestinal tract.

Authors:  Lei Zeng; Jiang Cao; Xing Zhang
Journal:  World J Gastroenterol       Date:  2005-10-21       Impact factor: 5.742

6.  Expression of serine peptidase inhibitor Kunitz type 1 in differentiated thyroid cancer.

Authors:  Chien-Liang Liu; Po-Sheng Yang; Ming-Nan Chien; Yuan-Ching Chang; Chi-Hsin Lin; Shih-Ping Cheng
Journal:  Histochem Cell Biol       Date:  2018-03-12       Impact factor: 4.304

7.  Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation.

Authors:  Karin List; Roman Szabo; Alfredo Molinolo; Virote Sriuranpong; Vivien Redeye; Tricia Murdock; Beth Burke; Boye S Nielsen; J Silvio Gutkind; Thomas H Bugge
Journal:  Genes Dev       Date:  2005-08-15       Impact factor: 11.361

8.  Reactive oxygen species regulate the generation of urokinase plasminogen activator in human hepatoma cells via MAPK pathways after treatment with hepatocyte growth factor.

Authors:  Kyung Hee Lee; Jae Ryong Kim
Journal:  Exp Mol Med       Date:  2009-03-31       Impact factor: 8.718

9.  The angiotensin IV analog Nle-Tyr-Leu-psi-(CH2-NH2)3-4-His-Pro-Phe (norleual) can act as a hepatocyte growth factor/c-Met inhibitor.

Authors:  B J Yamamoto; P D Elias; J A Masino; B D Hudson; A T McCoy; Z J Anderson; M D Varnum; M F Sardinia; J W Wright; J W Harding
Journal:  J Pharmacol Exp Ther       Date:  2010-01-19       Impact factor: 4.030

10.  (1S,2E,4S,7E,11E)-2,7,11-Cembratriene-4,6-diol semisynthetic analogs as novel c-Met inhibitors for the control of c-Met-dependent breast malignancies.

Authors:  Hassan Y Ebrahim; Mohamed M Mohyeldin; Mohammad M Hailat; Khalid A El Sayed
Journal:  Bioorg Med Chem       Date:  2016-09-13       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.